Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation-Reference-Cited by-同舟云学术

Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation

Published:2018-05 Issue: Volume:152 Page:298-306
ISSN:0223-5234
Container-title:European Journal of Medicinal Chemistry
language:en
Short-container-title:European Journal of Medicinal Chemistry

Author:

Yan Qi,Chen Yuzhe,Tang Baiyou,Xiao Qiang,Qu Rong,Tong Linjiang,Liu Jian,Ding Jian,Chen Yi,Ding Ning^ORCID,Tan Wenfu,Xie Hua,Li Yingxia

Funder

Shanghai Science and Technology Innovation Fund

Chinese Academy of Sciences

Publisher

Elsevier BV

Subject

Organic Chemistry,Drug Discovery,Pharmacology,General Medicine

Reference18 articles.

1. The ErbB/HER family of protein-tyrosine kinases and cancer;Roskoski;Pharmacol. Res.,2014

2. ERBB receptors and cancer: the complexity of targeted inhibitors;Hynes;Nat. Rev. Canc.,2005

3. Novel agents in development for advanced non-small cell lung cancer;Stinchcombe;Therapeutic Advances in Medical Oncology,2014

4. Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review;Chen;PLoS One,2013

5. Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib, Erlotinib, Afatinib, Dacomitinib, and Icotinib in the Treatment of Non-small-cell Lung Cancer: a Systematic Review;Ellis,2015

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rational design and synthesis of 2,4‐dichloro‐6‐methyl pyrimidine derivatives as potential selective EGFR^T790M/L858R inhibitors for the treatment of non‐small cell lung cancer;Archiv der Pharmazie;2024-02-21

2. Current scenario of pyrazole hybrids with in vivo therapeutic potential against cancers;European Journal of Medicinal Chemistry;2023-09

3. Recent Insights into Osimertinib Analogues against EGFR Positive Non-small Cell Lung Cancer;Current Topics in Medicinal Chemistry;2023-08

4. Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations;Medicinal Chemistry Research;2022-09-01

5. Search for potentially biased epidermal growth factor receptor (EGFR) inhibitors through pharmacophore modelling, molecular docking, and molecular dynamics (MD) simulation approaches;Journal of Biomolecular Structure and Dynamics;2022-01-11